Skip to content

Emergent Biosolutions EBS Preferred Stock, Shares Outstanding

Preferred Stock, Shares Outstanding at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
CorMedix logo
CorMedixCRMD
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Medline, Inc.
 logo
Medline, Inc. MDLN
Charles River Laboratories logo
Charles River LaboratoriesCRL
Rapid7 logo
Rapid7RPD

Other financials

Income statement

See full
Revenue$156.1M-29.7%
Gross profit$84.1M-37.1%
Operating income$10.5M-79.0%
Net income$6.8M-90.0%
EPS (diluted)$0.07-94.1%

Balance sheet

See full
Cash & equivalents$161.5M+5.7%
Total debt$584.6M-13.1%
Total equity$523.1M-5.4%
Total assets$1.3B-7.4%

Cash flow

See full
Operating cash flow-$33.8M-202%
CapEx$2.4M-33.3%
Free cash flow-$36.2M-145%

Valuation

See full
Market cap$411.74M+22.0%
Enterprise value$834.84M-2.6%
P/E3.6×
P/S0.6×+0.3×

Profitability

See full
Gross margin54.2%+19.0pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin20.8%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.1×-0.1×
Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's preferred stock, shares outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Emergent Biosolutions's preferred stock, shares outstanding?
Emergent Biosolutions (EBS) reported preferred stock, shares outstanding of $0 in Q1 2026.